$COLL - On our trading list. 2 Analysts have come out today and raised their price targets. Nice gain on the news.Collegium Pharmaceutical price target raised to $29 from $25 at H.C. WainwrightH.C. Wainwright analyst Oren Livnat raised his price target for Collegium Pharmaceutical to $29 from $25 saying the while the company's first-time 2020 revenue guidance is in-line with expectations, Xtampza ER upside is more important, and profitable, than Nucynta downside. The analyst keeps a Buy rating on the shares.Collegium Pharmaceutical price target raised to $36 from $28 at NeedhamNeedham analyst Serge Belanger raised his price target for Collegium Pharmaceutical to $36 from $28 and maintained a Buy rating after the company issued guidance for 2020 on Tuesday, saying Collegium expects Xtampza sales to grow to $150M-$160M in 2020 from $95M-$105M in 2019. He says there is potential for more significant Xtampza sales growth than implied by the 2020 guidance, but thinks Collegium erred on the conservative side given continued contraction across opioid markets. Based on Xtampza sales growth, the analyst expects Collegium to firmly cross the profitability threshold in 2020. $COLL, Collegium Pharmaceutical, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page